Carlyle confirms healthcare co-head Dahl has left firm

Bob Dahl, the co-head of Carlyle’s healthcare buyout team and a managing director for seven years, has left the firm “to explore some different options,” according to a Carlyle spokesman.

W. Robert Dahl, a managing director at The Carlyle Group and co-head of its global healthcare team, has departed the firm after seven years. Dahl departed the firm late last month, confirmed Christopher Ullman, Carlyle’s director of global communications. Ullman did not know specifics of Dahl’s future plans, but said that he was planning “to explore some different options.”

Dahl oversaw Carlyle’s many investments in the healthcare industry, including its acquisitions of orthodontics device maker Align Technology in May 2000 and health maintenance firm ConnectiCare Holdings in June 2001. Previously, he was managing director and co-head of the US healthcare group at Credit Suisse First Boston, where he worked for 13 years.

Karen Bechtel, the remaining co-head of the global healthcare team, will carry on as its sole leader. She joined Carlyle in July 2005 after 28 years at Morgan Stanley, where she was managing director of its private equity group.

Also last month, Carlyle’s healthcare team added William Johnston as a senior advisor. He had been chairman of Nashville, Tennessee-based Renal Care Group, a dialysis services provider, where he negotiated its $4.2 billion (€3.3 billion) sale to German healthcare firm Fresenius Medical Care last year.